This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

dapagliflozin (Forxiga®)

Reference No. 2745

Publication date:

Appraisal information

dapagliflozin (Forxiga®) 5 mg film-coated tablet
dapagliflozin (Forxiga®) 10 mg film-coated tablet

Company: AstraZeneca UK Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 08/06/2015

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA390) NICE GUIDANCE ISSUED MAY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) In the absence of a submission from the holder of the marketing authorisation, dapagliflozin (Forxiga®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
Statement of Advice (SOA)